Monoclonal antibody-based therapies for Waldenström's macroglobulinemia

Scott, 2012, Antibody therapy of cancer, Nat. Rev. Cancer, 12, 278, 10.1038/nrc3236 Hubert, 2012, Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy, Oncoimmunology, 1, 103, 10.4161/onci.1.1.17963 Weiner, 2015, Building better monoclonal antibody-based therapeutics, Nat. Rev. Cancer, 15, 361, 10.1038/nrc3930 Michaud, 2014, Tumor antigen-targeting monoclonal antibody-based immunotherapy: orchestrating combined strategies for the development of long-term antitumor immunity, Oncoimmunology, 3, 10.4161/21624011.2014.955684 Owen, 2003, Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia, Semin Oncol., 30, 110, 10.1053/sonc.2003.50082 McMaster, 2003, Familial Waldenstrom's macroglobulinemia, Semin Oncol., 30, 146, 10.1053/sonc.2003.50063 Treon, 2006, Characterization of familial Waldenstrom's macroglobulinemia, Ann. Oncol., 17, 488, 10.1093/annonc/mdj111 Yun, 2017, Waldenstrom macroglobulinemia: review of pathogenesis and management, Clin. Lymphoma Myeloma Leuk., 17, 252, 10.1016/j.clml.2017.02.028 Maloney, 2012, Anti-CD20 antibody therapy for B-cell lymphomas, N. Engl. J. Med., 366, 2008, 10.1056/NEJMct1114348 Cartron, 2004, From the bench to the bedside: ways to improve rituximab efficacy, Blood, 104, 2635, 10.1182/blood-2004-03-1110 Gertz, 2004, Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98), Leuk. Lymphoma, 45, 2047, 10.1080/10428190410001714043 Dimopoulos, 2002, Treatment of Waldenstrom's macroglobulinemia with rituximab, J. Clin. Oncol., 20, 2327, 10.1200/JCO.2002.09.039 Dimopoulos, 2002, Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia, Clin. Lymphoma, 3, 163, 10.3816/CLM.2002.n.022 Treon, 2004, Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia, Ann. Oncol., 15, 1481, 10.1093/annonc/mdh403 Castillo, 2020, Consensus treatment recommendations from the tenth international workshop for Waldenström macroglobulinaemia, Lancet Haematol., 7, e827, 10.1016/S2352-3026(20)30224-6 Wolach, 2010, Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature, Medicine (Baltimore), 89, 308, 10.1097/MD.0b013e3181f2caef Paul, 2019, Infusion-related reactions to rituximab: frequency, mechanisms and predictors, Expert Rev. Clin. Immunol., 15, 383, 10.1080/1744666X.2019.1562905 Kersten, 2010, Combining ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenström’s macroglobulinemia: final analysis of the phase I/II HOVON124/ECWM-R2 study, J. Clin. Oncol., 21 Treon, 2012, MYD88 L265P somatic mutation in Waldenström's macroglobulinemia, N. Engl. J. Med., 367, 826, 10.1056/NEJMoa1200710 Satterthwaite, 2000, The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective, Immunol. Rev., 175, 120, 10.1111/j.1600-065X.2000.imr017504.x Treon, 2012, MYD88 L265P somatic mutation in Waldenström's macroglobulinemia, N. Engl. J. Med., 367, 826, 10.1056/NEJMoa1200710 Treon, 2014, Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia, Blood, 123, 2791, 10.1182/blood-2014-01-550905 Dimopoulos, 2018, Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia, N. Engl. J. Med., 378, 2399, 10.1056/NEJMoa1802917 Tam, 2020, A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study, Blood, 136, 2038, 10.1182/blood.2020006844 Treon, 2011, Maintenance rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen, Br. J. Haematol., 154, 357, 10.1111/j.1365-2141.2011.08750.x Castillo, 2018, Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia, Br. J. Haematol., 181, 77, 10.1111/bjh.15148 Zanwar, 2019, Rituximab-based maintenance therapy in Waldenström macroglobulinemia: a case control study, J. Clin. Oncol., 37, 10.1200/JCO.2019.37.15_suppl.7559 Rummel, 2019, Blood, 134, 10.1182/blood-2019-121909 Teeling, 2006, The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20, J. Immunol., 177, 362, 10.4049/jimmunol.177.1.362 Teeling, 2004, Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas, Blood, 104, 1793, 10.1182/blood-2004-01-0039 Golay, 2000, Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis, Blood, 95, 3900, 10.1182/blood.V95.12.3900.012k14_3900_3908 Furman, 2017, Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study, Lancet Haematol., 4, e24, 10.1016/S2352-3026(16)30166-1 Gavriatopoulou, 2017, Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenstrom's macroglobulinemia, Leuk. Lymphoma, 58, 1506, 10.1080/10428194.2016.1233541 Mossner, 2010, Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity, Blood, 115, 4393, 10.1182/blood-2009-06-225979 Tomowiak, 2021, Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenstrom macroglobulinemia, Blood Adv., 5, 2438, 10.1182/bloodadvances.2020003895 Robak, 2011, New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies, BioDrugs, 25, 13, 10.2165/11539590-000000000-00000 Overdijk, 2015, Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma, MAbs, 7, 311, 10.1080/19420862.2015.1007813 Krejcik, 2016, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma, Blood, 128, 384, 10.1182/blood-2015-12-687749 Kastritis, 2021, Daratumumab-based treatment for immunoglobulin light-chain amyloidosis, N. Engl. J. Med., 385, 46, 10.1056/NEJMoa2028631 Castillo, 2020, Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia, Blood Adv., 4, 5089 Kashyap, 2016, Ulocuplumab (BMS-936564 /MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway, Oncotarget, 7, 2809, 10.18632/oncotarget.6465 Hunter, 2014, The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis, Blood, 123, 1637, 10.1182/blood-2013-09-525808 Xu, 2016, Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom macroglobulinaemia, Br. J. Haematol., 172, 735, 10.1111/bjh.13897 Cao, 2015, The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s macroglobulinemia, Leukemia, 29, 169, 10.1038/leu.2014.187 Cao, 2015, CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstrom macroglobulinaemia cells, Br. J. Haematol., 168, 701, 10.1111/bjh.13200 Ghobrial, 2014, Phase Ib study of the novel anti-CXCR4 antibody ulocuplumab (BMS-936564) in combination with lenalidomide plus lowdose dexamethasone, or with bortezomib plus dexamethasone in subjects with relapsed or refractory multiple myeloma, Blood, 124, 3483, 10.1182/blood.V124.21.3483.3483 Treon, 2005, Extended rituximab therapy in Waldenström's macroglobulinemia, Ann. Oncol., 16, 132, 10.1093/annonc/mdi022 Dimopoulos, 2007, Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide, J. Clin. Oncol., 25, 3344, 10.1200/JCO.2007.10.9926 Treon, 2009, Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia, Blood, 113, 3673, 10.1182/blood-2008-09-177329 Laszlo, 2010, Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study, J. Clin. Oncol., 28, 2233, 10.1200/JCO.2009.23.6315 Gavriatopoulou, 2017, BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years, Blood, 129, 456, 10.1182/blood-2016-09-742411 Treon, 2014, Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom’s macroglobulinemia, Blood, 124, 503, 10.1182/blood-2014-03-566273 Castillo, 2020, Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up, Blood Adv., 4, 3952, 10.1182/bloodadvances.2020001963